Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction

Coronary Artery Disease

Volumn 8, Issue 5, 1997, Pages 283-291

  Pedersen, Ole Dyg ^a,b   Gram, Joørgen ^a,b   Jeunemaitre, Xavier ^c   Billaud, Eliane ^c   Jespersen, Jørgen ^a,b  

^a ESBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c HÔPITAL BROUSSAIS   (France)

Author keywords

Angiotensin converting enzyme; Fibrinolysis; Myocardial infarction

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRANDOLAPRIL;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FIBRINOLYSIS; GENOTYPE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

EID: 0030789732     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199705000-00005     Document Type: Article

References (33)

1. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al., on behalf of the SAVE investigators: Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992, 327:669-677.
2. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al.: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992, 340:1173-1178.
3. Lonn EM, Yusuf S, Jha P, Montange TJ, Teo KK, Benedict CR, et al.: Emerging role of angiotensin converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994, 90:2056-2069.
4. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al.: Prevalence of total coronary occlusion during the early hours of transmural infarction. N Engl J Med 1980, 303:897-902.
5. Falk E: Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaque underlying fatal occlusive thrombi. Br Heart J 1983, 50:127-134.
6. Gram J, Jespersen J: A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction. Thromb Haemost 1987, 57:137-139.
7. Munkvad S, Gram J, Jespersen J: A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990, 11: 525-528.
8. Hamsten A, Walldius G, Szamosi A, Blombäck M, de Faire U, Dahlen G, et al.: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, 2:3-9.
9. Pedersen OD, Gram J, Bagger H, Keller N, Jespersen J: Regulation of tissue-type plasminogen activator mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease. Possible unfavourable effects of diuretics. Coronary Artery Dis 1994, 5:617-623.
10. Smith D, Gilbert M, Owen WG: Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985, 66:835-839.
11. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995, 95:995-1001.
12. van Leeuwen RTJ, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G: Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994, 90:362-368.
13. Feener EP, Northrup JM, Aiello LP, King GL: Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995, 95:1353-1362.
14. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation. 1993, 87:1969-1973.
15. The TRACE study group: The trandolapril cardiac evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol 1994, 73:44C-50C.
16. Kluft C, Verheijen JH: Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 1990, 4 (supp 2):155-161.
17. Alhenc-Gelas F, Weare J, Johnson AL, Erdos EG: Measurement of human converting enzyme level by direct radioimmunoassay. J Lab Clin Med 1983, 101:83-96.
18. Buttery JE, Stuart S: Studies on zinc and angiotensin-converting enzyme. Clin Chem Acta 1993, 217:213-216.
19. Sambrook J, Fritch EF, Maniatis T (eds): Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor press; 1992.
20. Rigat B, Hubert C, Corvol P, Soubrier F: The ACE/ID polymorphism detected by PCR amplification. Nucl Acids Res 1992, 20:1433.
21. Shaumgam V, Sell KW, Saha BK: Mistyping ACE heterozygotes. PCR Methods Appl 1993, 3:120-121.
22. Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalovel JA, Ward RH: Angiotensin converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation 1995, 91:2120-2124.
23. Matthews JNS, Altman DG, Campell MJ, Royston P: Analysis of serial measurements in medical research. Br Med J 1990, 300:230-235.
24. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al.: A prospective evaluation of an angiotensin converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995, 332:706-711.
25. Cambien F, Porer O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al.: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992, 359:641-644.
26. Jansson JH, Boman K, Nilsson TK: Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993, 44:485-488.
27. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA: Effects of captopril therapy on endogenous fibrinolysis in men with recent uncomplicated myocardial infarction. J Am Coll Cardiol 1994, 24:67-73.
28. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Sourbner F: An insertion/deletion polymorphism in the angiotensin 1-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
29. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al.: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin 1-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992, 51:197-205.
30. Brommer EJP: The level of extrinsic plasminogen activator (t-PA) during clotting determines the rate of fibrinolysis. Inefficiency of activators added afterwards. Thromb Res 1984, 34:109-115.
31. Munkvad S, Gram J, Jespersen J: Increase of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in plasma after thrombolytic therapy of patients with myocardial infarction. A randomized, placebo-controlled study. Fibrinolysis 1992, 6:45-50.
32. Andreotti F, Roncaglioni MC, Hackett DR, Khan MI, Regan T, Haider AW, et al.: Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990, 16:1553-1560.
33. Gram J, Kluft C, Jespersen J: Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemost 1987, 58:817-821.